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Eﬀects of psilocybin therapy on personality
structure
Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ,
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Objective: To explore whether psilocybin with psychological support
modulates personality parameters in patients suﬀering from treatment-
resistant depression (TRD).
Method: Twenty patients with moderate or severe, unipolar, TRD
received oral psilocybin (10 and 25 mg, one week apart) in a supportive
setting. Personality was assessed at baseline and at 3-month follow-up
using the Revised NEO Personality Inventory (NEO-PI-R), the
subjective psilocybin experience with Altered State of Consciousness
(ASC) scale, and depressive symptoms with QIDS-SR16.
Results: Neuroticism scores signiﬁcantly decreased while Extraversion
increased following psilocybin therapy. These changes were in the
direction of the normative NEO-PI-R data and were both predicted, in
an exploratory analysis, by the degree of insightfulness experienced
during the psilocybin session. Openness scores also signiﬁcantly
increased following psilocybin, whereas Conscientiousness showed
trend-level increases, and Agreeableness did not change.
Conclusion: Our observation of changes in personality measures after
psilocybin therapy was mostly consistent with reports of personality
change in relation to conventional antidepressant treatment, although
the pronounced increases in Extraversion and Openness might constitute
an eﬀect more speciﬁc to psychedelic therapy. This needs further
exploration in future controlled studies, as do the brain mechanisms of
postpsychedelic personality change.
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Signiﬁcant outcomes
• Personality trait Neuroticism decreased, while traits Extraversion, Conscientiousness (trend-level), and
Openness all increased from baseline to the 3-month follow-up after psilocybin-facilitated therapy for
treatment-resistant depression.
• An exploratory analysis revealed that the degree of insightfulness during the psychedelic experience
predicted changes in Neuroticism and Extraversion.
• Where changes in Neuroticism and Conscientiousness are consistent with what has been observed pre-
viously among patients responding to antidepressant treatment, the pronounced increases in
Extraversion and Openness might constitute an eﬀect more speciﬁc to therapy with a psychedelic.
Limitations
• Relatively small sample size of 20 patients suﬀering treatment-resistant depression.
• Open-label design and absence of a control condition.
• Two-thirds of the patients in this study were men, limiting extrapolation to the general population
where rates of treatment-resistant depression are marginally higher in women than in men.
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Major depression is a commonly occurring disor-
der associated with high morbidity, socio-eco-
nomic burden, and rates of completed suicide (1,
2). It aﬀects 10–15% of the general population (2–
4) and has been ranked by The World Health
Organization (WHO) as the fourth leading con-
tributor to the global burden of disease (5), with a
forecast of becoming number one by 2030 (6).
Almost half of the cost and disease burden caused
by depression has been attributed to treatment-
resistant depression (TRD) (7, 8), typically deﬁned
as ‘a poor response to two adequate trials of diﬀer-
ent classes of antidepressants’ (9). TRD is associ-
ated with longer duration and higher severity of
the disease, more protracted functional impair-
ment, and poses a signiﬁcant personal and public
health problem (8). TRD aﬀects about 30% of
patients with major depression and up to 60% if
TRD is deﬁned as absence of remission (7, 10).
The poor prognosis and socio-economic burden
associated with TRD give ground for research
focusing on therapeutic interventions with alterna-
tive strategies to conventional pharmaceutical and
therapeutic approaches.
Beginning in the 1990s (11, 12), neurobiological
and psychiatric interest in classic serotonergic psy-
chedelic compounds, such as psilocybin, N,N-
dimethyltryptamine (DMT), and lysergic acid
diethylamide (LSD), gradually re-emerged after
decades of being suppressed (13, 14). Recent pilot
studies point to the potential of psychedelic-
assisted therapy to treat conditions including
tobacco (15) and alcohol (16) addiction, obsessive-
compulsive disorder (17), end of life anxiety/de-
pression (18–20), major depression (21), and TRD
(22, 23) – (see Carhart-Harris & Goodwin, 2017
for a review (24)). Intriguingly, the treatment eﬀect
in these trials appears to last for several months –
much longer than the pharmacological presence of
the actual compounds (25, 26).
Typically, psychedelic-assisted therapy involves
only one or two sessions in which a moderate to
high dose of a psychedelic compound is given in a
supportive environment (27, 28) with the intention
of evoking ‘peak’ (29) or ‘mystical-type’ (30, 31)
experiences, characterized by disintegration of ego
boundaries and an accompanying sense of con-
nectedness (32, 33), oneness, or unity (34). This
treatment paradigm diﬀers from the approach of
long-term daily pharmacological intervention asso-
ciated with conventional antidepressant medica-
tion.
The mechanisms underlying the long-lasting
therapeutic eﬀects of psychedelic therapy remain
unknown. There appears to be a relationship
between the therapeutic outcome and the subjec-
tive experiences during the psychedelic sessions
(18, 27, 35–38). Moreover, psilocybin and LSD
may increase the NEO-PI-R (39) personality trait
Openness to Experience (or simply ‘Openness’) in
healthy volunteers after a single dose (40, 41).
Interestingly, and constituting a possible link
between the quality of the experience and the
impact on personality, in the subgroup of partici-
pants who had mystical experiences during their
psilocybin session, Openness remained signiﬁcantly
higher than baseline more than 1 year after the ses-
sion (40).
Openness is considered to be one of the ﬁve
major dimensions of personality and is linked to
Openness to new ideas and values, imagination,
aesthetic appreciation, novelty-seeking, non-con-
formity, and creativity (39). In major depression,
eﬀective treatment with antidepressants has been
shown not only to increase Openness scores but
also to signiﬁcantly aﬀect three of the remaining
four NEO-PI-R personality domains; decreasing
Neuroticism, increasing Extraversion and Conscien-
tiousness, with Agreeableness remaining unchanged
(42).
The aim of the present study was to explore
whether psilocybin with psychological support
modulates personality parameters in patients suf-
fering from treatment-resistant depression, to
investigate whether these changes relate to the
quality of the psychedelic experience and to inves-
tigate whether such modulations could potentially
help us understand the long-lasting nature of psy-
chedelic-assisted therapy.
Methods
The study was approved by the National Research
Ethics Service (NRES) London – West London,
sponsored and approved by Imperial College Lon-
don’s Joint Research and Complication Organisa-
tion (JRCO), adopted by the National Institute of
Health Research (NIHR) Clinical Research Net-
work (CRN), and reviewed and approved by
Medicines and Healthcare products Regulatory
Agency (MHRA).
Participants
Twenty patients suﬀering treatment-resistant
depression were enrolled in this open-label feasibil-
ity study. The main inclusion criteria were: unipo-
lar major depression of at least moderate severity
(17+ on the 21-item HAM-D) and no improvement
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despite two courses of pharmacologically distinct
antidepressant medications for an adequate dura-
tion (6 weeks minimum) within the current epi-
sode. Main exclusion criteria were: a current or
previously diagnosed psychotic disorder or an
immediate family member with a diagnosed psy-
chotic disorder. Five patients had previously tried
a psychedelic drug; in four of ﬁve cases, this had
occurred in recreational contexts in early adult-
hood. All but three had undergone psychological
therapy/counseling (23).
Study procedure
Full details of study procedures have been pub-
lished previously (22, 23). Brieﬂy, the ﬁrst phase of
screening involved a scripted telephone interview,
which was used to prescreen for the major inclu-
sion/exclusion criteria. Suited candidates were
invited for a screening visit at the Imperial Clinical
Research Facility (ICRF) at the Hammersmith
hospital where informed consent was taken. A
detailed history of both physical and mental (using
MINI-5) health, routine blood tests, ECG, urine
test for drugs of abuse and pregnancy where rele-
vant, breathalyzer, and a number of baseline
assessments, including the NEO-PI-R, were
acquired during this visit. Eligible patients
attended a preparation visit, followed by two dos-
ing sessions, separated by one week. In the ﬁrst ses-
sion, patients received 10 mg psilocybin, and in the
second, 25 mg. The second session was the focus
of the therapeutic process, as only this dose was
predicted to induce lasting therapeutic eﬀects.
After capsule ingestion, patients laid with their
eyes closed while listening to a music playlist (27).
Two therapists adopted a non-directive, supportive
approach, allowing the patient to experience a
mostly uninterrupted introspection. Patients came
back one day and again one week after the 25 mg
session for integration of the experience.
Measures
Personality was assessed using the NEO-PI-R
instrument (39), which covers 5 domains, Neuroti-
cism (anxious, insecure, emotional), Extraversion
(sociable, optimistic, talkative), Openness to Expe-
rience (or short: Openness) (curious, imaginative,
creative), Conscientiousness (hard-working, ambi-
tious, persistent), and Agreeableness (good-nat-
ured, cooperative, helpful). Each domain has six
facets, each of which contains eight items that are
rated by respondents using a 5-point Likert-type
scale ranging from strongly disagree to strongly
agree. NEO-PI-R raw scores were standardized as
T-scores (M = 50, SD = 10) using the combined-
sex norms reported in the NEO-PI-R manual.
Cohen’s d eﬀect size was also calculated from raw




experience under psilocybin was assessed using the
altered state of consciousness questionnaire (ASC)
(43). This self-rated instrument captures the acute
quality of the psychedelic experience and covers
factors such as insightfulness, blissfulness, experi-
ence of unity, and spirituality. The 16-item Quick
Inventory of Depressive Symptoms, (QIDS-SR16)
was employed to assess depressive symptoms at
baseline and at selected time points. Change in
severity of depressive symptoms, as assessed with
diﬀerent measures, from baseline to follow-up time
points have been published separately (23).
Analysis
Baseline vs. 3-month follow-up NEO-PI-R scores
were compared using two-tailed paired t-tests, and
false discovery rate (FDR) method with a thresh-
old of 0.05 applied. Results are reported as
mean  SD. A standard threshold for deﬁning
treatment response (≥50% reduction in QIDS
score from baseline) was used to separate patients
into responders and non-responders. Bivariate cor-
relations were tested using Pearson’s correlation
coeﬃcient; to test whether any of 4 ASC subfactors
related to the ‘peak’ experience, insightfulness,
blissful state, ‘experience of unity’, and spiritual
experience (37) were related to changes in any of
the NEO-PI-R trait scores (baseline vs. 3-month
follow-up), and to test associations between
changes in NEO-PI-R scores (trait and facet
scores) and QIDS scores. These correlation analy-
ses were uncorrected for multiple comparisons and
should be regarded as explorative in nature.
Results
Out of the 20 patients included in the trial, 18 met
criteria for severe or very severe depression at base-
line (QIDS-16 score of ≥16), and the remaining
two suﬀered ‘moderate’ depression (QIDS-16 score
≥11, <16). As described in (23), one patient decided
not to complete most follow-up measures, includ-
ing NEO-PI-R at 3-month follow-up, therefore
leaving 19 complete datasets (6 females and 13
males; mean age = 44.7  10.9; 27–64).
Personality changes from baseline to 3-month follow-up
As listed in Table 1 and illustrated in Fig. 1, three
out of the ﬁve NEO-PI-R domain scores
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signiﬁcantly changed from baseline to 3-month
postpsilocybin treatment: Neuroticism scores
decreased (T-score change: 5.7, P = 0.002),
whereas both Extraversion and Openness increased
(T-score changes: 6.5, P < 0.001, and 4.9,
P = 0.012, respectively). An increase in T-score of
3.2 in Conscientiousness was only borderline signif-
icant (P = 0.086). Eleven NEO-PI-R facet scores,
all arising from these four domains, changed sig-
niﬁcantly from baseline to 3-month follow-up, ten
of these changes surviving FDR correction (these
are listed in Table 1 and Fig. 2). Cohen’s d eﬀect
sizes calculated from the raw scores are listed in
Table 1.
Personality changes vs. changes in depression scores
When dividing patients into clinical responders
(n = 7) vs. non-responders (n = 12) at 3 months, a
group comparison revealed that among respon-
ders, Neuroticism score had decreased more from
baseline to 3-month follow-up than among non-
responders (23  17 vs. 6  8 respectively,
P = 0.038), whereas Conscientiousness score had
increased more among responders than among
non-responders over the same period (15  11 vs.
0  12 respectively, P = 0.017). Responders did
not diﬀer signiﬁcantly from non-responders with
regard to personality changes within the 3 other
domains (Openness: 11  21 vs. 7  6, P = 0.623;
Agreeableness: 1  7 vs. 1  8, P = 0.577;
Extraversion: 17  10 vs. 9  11, P = 0.105). In
an exploratory analysis none of the 5 NEO-PI-R
domain changes from baseline to 3-month follow-
up signiﬁcantly correlated with change in either
QIDS or BDI depression scores at 3 months.
There were positive associations between decreases
in Neuroticism and decreases in QIDS scores
(r = 0.41, P = 0.080), and a negative association
between increases in Extraversion and decreases in
QIDS (r = 0.42, P = 0.071). These relationships,
however, did not reach statistical signiﬁcance.
Relationship between Peak Experience and personality changes
The degree of insightfulness experienced during the
focal 25 mg psilocybin session was signiﬁcantly
associated with a reduction in Neuroticism score
(r = 0.47, P = 0.043), as well as with an increase
in Extraversion score (r = 0.54, P = 0.017). Also,
spiritual experience was signiﬁcantly positively cor-
related with increased Extraversion from baseline
to 3-month follow-up (r = 0.47, P = 0.048),
whereas positive relationships between





T-score Change P-value Cohen’s d
Neuroticism (N) 76.6 70.9 5.7 0.002 0.571
Extraversion (E) 31.1 37.6 6.5 0.000 0.716
Openness to Experience (O) 52.7 57.6 4.9 0.012 0.437
Agreeableness (A) 46.8 46.7 0.1 0.953 0.006
Conscientiousness (C) 29.9 33.1 3.2 0.086 0.273
Anxiety (N1) 70.3 66.6 3.7 0.037 0.403
Angry-Hostility (N2) 67.6 65.4 2.2 0.222 0.277
Depression (N3) 77.8 71.2 6.6 0.006 0.661
Self-consciousness (N4) 68.1 63.6 4.5 0.016 0.366
Impulsiveness (N5) 57.8 56.3 1.4 0.446 0.184
Vulnerability (N6) 78.6 71.3 7.3 0.004 0.706
Warmth (E1) 34.7 41.8 7.1 0.001 0.604
Gregariousness (E2) 37.7 42.2 4.5 0.011 0.503
Assertiveness (E3) 43.9 45.9 2.0 0.152 0.304
Activity (E4) 35.2 38.3 3.1 0.071 0.442
Excitement seeking (E5) 43.1 44.9 1.8 0.279 0.171
Positive emotions (E6) 27.8 36.1 8.3 0.000 0.740
Openness to Fantasy (O1) 58.9 57.2 1.7 0.415 0.193
Openness to
Aesthetics (O2)
53.2 56.2 3.0 0.157 0.244
Openness to Feelings (O3) 52.7 54.0 1.3 0.589 0.111
Openness to Actions (O4) 41.2 48.8 7.5 0.002 0.783
Openness to Ideas (O5) 51.5 55.2 3.7 0.077 0.324
Openness to Values (O6) 50.0 56.3 6.3 0.001 0.692
Trust (A1) 36.8 40.0 3.3 0.085 0.372
Straightforwardness (A2) 47.8 46.6 1.2 0.478 0.120
Altruism (A3) 44.8 43.2 1.7 0.318 0.177
Compliance (A4) 43.8 43.0 0.8 0.685 0.069
Modesty (A5) 58.3 55.9 2.4 0.163 0.199
Tender-mindedness (A6) 56.2 58.9 2.7 0.274 0.215
Competence (C1) 26.7 33.0 6.3 0.011 0.743
Order (C2) 42.4 40.5 1.9 0.376 0.138
Dutifulness (C3) 38.2 41.3 3.1 0.191 0.250
Achievement striving
(C4)
33.1 36.4 3.3 0.110 0.294
Self-discipline (C5) 22.9 27.6 4.7 0.010 0.465
Deliberation (C6) 47.2 46.6 0.6 0.662 0.080
Domains and facets in bold represent scores that showed significant difference
between baseline and 3-month follow-up with Student’s paired t-tests and that sur-
vived FDR correction for multiple comparisons. Thus, facet anxiety is the only of the
11 significantly changed facet scores not to survive the FDR correction. Cohen’s d
effect sizes were calculated from the raw mean and SD scores at baseline and 3-
month follow-up.
Fig. 1. Trait T-scores scores at baseline (solid thick line) and
at 3-month follow-up (dotted line). T-scores calculated with
the use of means and standard deviations from a combined
sample of 500 healthy women and 500 healthy men (NEO-PI-
R manual). The normative data (solid thin line) are repre-
sented by normalized scores of 50.
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Extraversion and scores of blissful state and Expe-
rience of unity only reached borderline signiﬁcance
levels (r = 0.41, P = 0.081, and r = 0.42,
P = 0.075, respectively). None of the Peak Experi-
ence-related ASC scores were associated with
changes in Openness or Conscientiousness.
Baseline personality scores as predictors of Peak Experience
Among the 5 NEO-PI-R domains assessed at base-
line, only Openness showed a borderline signiﬁcant
association with any of the ratings of Peak Experi-
ence-related ASC subdimensions, assessed in rela-
tion to the focal 25 mg psilocybin session; thus, a
positive association between baseline Openness and
blissful state reached borderline signiﬁcance
(r = 0.43, P = 0.063). In an exploratory analysis,
we tested whether individual variation in Openness
scores at baseline correlated with the Peak Experi-
ence. Correlation analysis revealed that two facets
of this personality domain, Openness to Fantasy
(r = 0.50, P = 0.030) and Openness to Aesthetics
(trend-level; r = 0.45, P = 0.054) were positively
associated with blissful state experienced during
the psychedelic experience. There were also trend-
level positive associations between Openness to
Fantasy at baseline and both Experience of unity
and spiritual experience during the experience
(r = 0.41, P = 0.080, and r = 0.43, P = 0.069,
respectively).
Baseline personality scores as predictors of treatment response
Neuroticism scores at baseline showed a negative
correlation with improvement in depression scores
at 3 months at trend level (r = 0.42, P = 0.075),
such that patients with higher Neuroticism scores
at baseline showed reduced clinical improvement
after psilocybin. Treatment responders after
3 months did not signiﬁcantly diﬀer from non-
responders on any of the 5 domain scores at base-
line.
Discussion
In this open-label study of psilocybin therapy for
treat-resistant major depression, clinical improve-
ment among patients was found to be accompa-
nied by signiﬁcant changes in personality
measures. Thus, from baseline to 3-month follow-
up, the NEO-PI-R ‘Big Five’ score of Neuroticism
signiﬁcantly decreased, Extraversion and Openness
scores signiﬁcantly increased, Conscientiousness
showed a trend-level increase, and no changes were
seen in Agreeableness. A total of 11 of the 30
NEO_PI-R facets also signiﬁcantly changed, with
10 of these surviving multiple comparisons correc-
tion. To our knowledge, this is the ﬁrst time per-
sonality measures have been reported to change
among patients undergoing psychedelic therapy
for depression. These results expand on the ﬁnd-
ings of psilocybin-induced changes of personality
traits in healthy volunteers (40).
Overall, the detected pre- to post-treatment
changes in both trait and facet scores in our trial
corresponded well with observations from a study
of patients who successfully underwent pharma-
cotherapy, mostly with selective serotonin reup-
take inhibitors (SSRIs), for major depression (42).
More speciﬁcally, the same four of ‘the Big Five’
traits changed in the two trials and in the same
direction – that is toward the personality proﬁle of
healthy populations (although Conscientiousness
only at trend-level in our study). Also several of
the facet changes we saw here overlapped with
those reported by Costa et al. (42). More speciﬁ-
cally, patients in both trials displayed decreases on
the Neuroticism facets of depression, vulnerability,
self-consciousness, and anxiety. Increases in
Extraversion included the facets of warmth and
Fig. 2. Facet T-scores scores at baseline (solid thick line) and at 3-month follow-up (dotted line), with normative data normalised to
50 (solid think line).
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positive emotions. Increases in Conscientiousness
included the facets of competence and self-disci-
pline. Means and standard deviations of NEO-PI-
R scores were not reported by Costa et al., hinder-
ing calculation of eﬀect sizes for direct comparison
with our ﬁndings (listed in Table 1).
Pre- to post-treatment changes in Neuroticism, a
known vulnerability marker for aﬀective disorders
(44, 45), and increases in Extraversion, a trait asso-
ciated with general positive aﬀect (46), have previ-
ously been found to be signiﬁcantly correlated with
SSRI/SNRI-induced reduction in depression sever-
ity (47). In accord with this, QIDS decreases in our
study were associated with decreases in Neuroti-
cism and increases in Extraversion, albeit at only
trend-level signiﬁcance. In contrast, increased
Openness did not correlate with treatment response
and neither was it diﬀerent between responders
and non-responders. This is consistent with the
principle that Openness to Experience is orthogonal
to anxiety or depression symptoms (46) – although
there are also some ﬁndings to suggest there is a
moderate relationship between Openness and psy-
chological wellbeing (48, 49). Support for the
change in Openness score potentially being an
addition to, rather than a direct eﬀect of, improved
aﬀective symptoms can be taken from a recent nat-
uralistic survey among more than 200 individuals
for whom symptomatology and personality mea-
sures were assessed online, of a psychedelic experi-
ence conducted by our team. Here, Openness
changed equally for depressed and non-depressed,
whereas changes in Neuroticism were only
observed among depressed individuals (manuscript
in prep, data not shown).
In addition, an extensive meta-analysis of per-
sonality changes after therapeutic interventions
revealed that trait Openness was the only one
among the ‘Big Five’ traits that did not robustly
change (50). For a more direct comparison of our
NEO-PI-R domain changes to previous treatment
studies in depression, we identiﬁed 5 patient sam-
ples from 3 diﬀerent trials in major depression
where NEO-PI-R changes were reported after
treatment with antidepressant medication (47, 51,
52) – although, in one of these studies, only Neu-
roticism scores were reported (51). Across these tri-
als, SSRIs (citalopram, paroxetine, sertraline, and
ﬂuoxetine) (47, 51, 52), a norepinephrine-dopa-
mine reuptake inhibitor (bupropion) (51, 52), a
serotonin–norepinephrine reuptake inhibitor (ven-
lafaxine) (52), a reversible inhibitor of monoamine
oxidase A (moclobemide) (51), a non-selective irre-
versible monoamine oxidase inhibitor (phenelzine)
(52), and a norepinephrine reuptake blocker (de-
sipramine) (47) were used in relevant clinical doses
over 8–20 weeks to treat a total number of 469
patients suﬀering major depression. The pre- and
post-treatment NEO-PI-R domain score data pre-
sented in these publications allowed for calculation
of Cohen’s d eﬀect sizes.
Interestingly, changes in Neuroticism, Agreeable-
ness, and Conscientiousness scores were very simi-
lar to what was seen in our study (sample size-
weighted average Cohen’s d; 0.59, 0.04, and 0.18
respectively, vs. 0.57, 0.01, and 0.27 in our
study). In contrast, Cohen’s d eﬀect sizes for Open-
ness in our trial were more than 3 times larger
(0.44 vs. an average of 0.13) and more than 2 times
larger for Extraversion (0.72 vs. 0.32) than the
average eﬀect sizes from the comparison trials. Of
note, the lack of full consistency regarding follow-
up (ranging from 8 to 20 weeks) means that inter-
pretations of direct Cohen’s d comparisons across
studies should be made cautiously.
From the present data, it is hard to infer that the
NEO-PI-R changes, and in particular changes in
Neuroticism and Extraversion, represent trait and
not state changes. However, a 3-month enduring
change might suggest that it might not just be a
state artifact – a notion also supported by the
long-lasting psilocybin-induced increases in Open-
ness observed in healthy individuals (40).
Whereas the facet scores were not reported in
these studies, none of the Openness facets were
found to be signiﬁcantly changed after successful
antidepressant treatment in the study by Costa
et al. (42). In contrast, the facets Openness to
actions and to values signiﬁcantly increased in our
study. The facet Openness to Actions pertains to
not being set in one’s way, and instead, being ready
to try and do new things. Openness to Values is
about valuing permissiveness, open-mindedness,
and tolerance. These two facets therefore reﬂect an
active approach on the part of the individual to try
new ways of doing things and consider other peo-
ples’ values and/or worldviews. Thus, treatment-
induced modiﬁcation of Openness and its facets
following psilocybin treatment might be an out-
come separate and additional to the changes that
have previously been seen with antidepressant
treatment for example (50). Whether the pattern of
change in personality measures, in particular with
regard to Openness, is diﬀerent between psychede-
lic therapy and conventional pharmacotherapy
(e.g., with SSRIs) should be tested in the future. In
our laboratory, we are currently setting up a treat-
ment study in major depression where the eﬀects
of such treatment models can be compared
directly.
Studies investigating the relationship between
psychedelics and personality among non-depressed
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individuals are worth considering in this regard.
Follow-up evaluations of work from the 1950–60s
have suggested the possibility of long-lasting
eﬀects on personality, resulting from the use of
psychedelics (53, 54), and this has since been con-
ﬁrmed in a series of modern, controlled studies.
For example, a single high dose of psilocybin with
psychological support was found to facilitate long-
lasting increases in trait Openness in psychedelic-
na€ıve healthy individuals (40). Similarly, adminis-
tration of LSD in a brain imaging setting led to
discrete increases in Openness scores in healthy vol-
unteers assessed at 2 weeks after the LSD session
(41) although this was not replicated in a recent
LSD study with longer postsession follow-up time
points (1 month and 12 months) (55). Recently,
administration of the entactogen, 3,4-methylene-
dioxy-methamphetamine (MDMA), in conjunc-
tion with psychotherapy has been shown to lead to
increases in Openness, as well as decreases in Neu-
roticism, in patients being treated for post-trau-
matic stress disorder (56). Regular ceremonial use
of the psychedelic brew, ayahuasca, was associated
with higher Openness scores when compared with
matched non-ayahuasca using controls (57) and
self-reported lifetime recreational psychedelic use
correlated positively with Openness scores in a
large online survey (58), as well as in a separate
brain imaging trial (D. Erritzoe, under review).
Interestingly, in the latter trial, it was the Openness
to Actions and Openness to Values subfactors that
correlated with lifetime psychedelic use (D. Errit-
zoe, under review).
It is well established that trait Openness corre-
lates reliably with liberal political perspective (58–
61). Given that psychedelics have been found to
modulate Openness and other work has shown that
Openness and liberal political perspectives are
related, it is reasonable to surmise that psychede-
lics may modulate political perspective also.
Indeed, work in the past has found associations
between psychedelic use and attitudes of ‘personal
liberty’ and ‘foreign policy liberalism’ (53), as well
as concern for others, irrespective of culture of ori-
gin (62). Moreover, a series of recent studies have
further endorsed a general relationship between
psychedelic use and greater pro-environmental
behavior (63) and nature-relatedness (58, 63, 64),
as well as liberal (60) and antiauthoritarian per-
spectives (58, 64). The apparent link between
Openness and a generally liberal worldview may be
attributed to the notion that people who are more
open to new experiences are also less personally
constrained by convention and that this freedom
of attitude extends into every aspect of a person’s
life, including their political orientation (65).
It is worth noting that the Openness score among
patients entering our trial was already slightly
higher at baseline (2.7 T-score points higher, illus-
trated in Fig. 1) than the normative scores
reported in the NEO-PI-R manual (66) and
increased another 4.9 T-score points following the
intervention. Openness therefore diﬀered from the
other three personality traits in that it changed
from an already higher than average baseline to an
even higher level 3 months later. In contrast, the
other traits all changed in the direction of norma-
tive data (see Fig. 1), for example, Neuroticism
decreased from an abnormally high level at base-
line, whereas Conscientiousness (trend-level) and
Extraversion both increased from an abnormally
low baseline, and thus toward the values of healthy
non-depressed individuals (66). The explanation
for Openness being relatively high at baseline may
be found in the nature of the trial; people who are
less Open to Experience are probably less likely to
volunteer for a novel treatment involving a psyche-
delic drug. In support of this interpretation,
healthy volunteers who took part in an invasive
PET brain imaging study speciﬁcally had signiﬁ-
cantly higher Openness scores when compared to
Danish NEO-PI-R norm data (67).
The observation that a single profound psyche-
delic experience can lead to lasting changes in per-
sonality is intriguing, especially when considering
the relative stability of personality once adulthood
is reached. Longitudinal studies have shown that
personality changes after age 30 are typically sub-
tle and/or gradual, that is around 1–2 T-score
points per decade, with a subtle drop in Openness
and Extraversion scores and a slight increase
Agreeableness in older age (68). However, as longi-
tudinal studies of personality are typically con-
ducted with very long intervals between sampling
of personality traits, the personality literature
overall provides limited evidence for how fast or
slow personality trait change can occur (50). Thus,
our observation of relatively marked changes in
personality within a short time span challenges the
assumption that personality can only change
slowly, gradually, and subtly. A systematic review
of more than 200 studies concluded that enduring
and large changes in personality are obtainable
through a range of therapeutic interventions (50)
but to our knowledge, none so rapidly or as
marked as with psychedelics. The phenomenon of
psychological ‘quantum change’ may be relevant
in this regard (69), where one’s outlook and behav-
ior rapidly and profoundly changes – such as with
sudden religious conversion experiences.
Of the acute experience factors that most related
to personality change, greater insightfulness during
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the 25 mg experience was found to be correlated
with decreased Neuroticism as well as increased
Extraversion at 3 months. Also, greater spiritual
experience was correlated with increased Extraver-
sion. Borderline relationships were seen between
increased Extraversion and higher blissful state and
Experience of unity scores. The observation that
the long-lasting impact of psychedelic therapy – in
this case on measures of Extraversion and Neuroti-
cism – may depend on their ability to occasion pro-
found insights and ‘peak’ (29) or mystical-type (70)
experiences is supported by a number of modern
clinical trials, where the magnitude of such peak or
mystical experience is often predictive of positive
clinical outcome (16, 18, 20, 35, 37). Problems
related to the potentially non-secular meaning of
‘mystical experience’ have recently been raised (24)
but if the construct has predictive value, then it at
least forces us to ask ‘why’? With the exception of
spiritual Experience, blissful state, and unity pre-
dicting increased Extroversion, the major personal-
ity changes observed here were not strongly
predicted by factors relevant to ‘mystical experi-
ence’. It is interesting that the somewhat more con-
crete notion of insightfulness showed more
compelling relationships with the personality
changes in the present study. Importantly, correla-
tion analyses in this paper were not corrected for
multiple comparisons and should therefore be con-
sidered exploratory in nature. In addition, it
should here be noted that the sample size of the
present study is modest, in particular when divid-
ing it further into subgroups of responders and
non-responders. This limits our statistical power to
detect small eﬀect sizes that may be of clinical
importance, and future randomized and placebo-
controlled trials with larger sample sizes will be
important to further substantiate the ﬁndings from
the present study.
These present ﬁndings are somewhat inconsis-
tent with those of MacLean et al. who found that
individuals who had a ‘mystical-type’ experience
were more likely to show sustained increases in
Openness several months later (40). This may be
explained by diﬀerences in the study populations,
diﬀerences in the questionnaires that were used to
assess subjective psilocybin experience, attitudes,
and philosophy of support provided by the
research staﬀ (e.g., relative emphasis on mystical
experience during preparation), or by the time
delay at which personality was assessed (i.e.,
3 months in the present study and over 12 in the
MacLean study).
The neurobiological correlates of personality
change after psychedelics have yet to be investi-
gated. However, positron emission tomography
(PET) imaging has revealed that brain serotonin
2A receptor levels, the key initiator of psychede-
lics’ signature psychological and neurophysiologi-
cal eﬀects (71) are positively associated with
Neuroticism scores (67). In fact, the same Neuroti-
cism facet scores that were found to decrease the
most after psilocybin therapy in the present study
(vulnerability anxiety, depression, and self-con-
sciousness) were also the facets most strongly cor-
related with serotonin 2A receptor binding in a
sample of 83 healthy volunteers (67). Also, the trait
‘dysfunctional attitude’, which is associated with
pessimistic beliefs, has been associated with ele-
vated serotonin 2A receptor levels in both
depressed patients (72) and individuals recovered
from depression (73). It has been suggested that
serotonin 2A receptor upregulation is secondary to
deﬁcient stimulation with serotonin (72), which is
consistent with the observation that downregula-
tion of 2A receptors is associated with treatment
with antidepressant drugs that elevate synaptic
serotonin (Muguruza et al., 2014).
To our knowledge, although Openness has not
been directly associated with serotonin 2A receptor
regulation, and 2A receptor levels did not appear
to mediate an association between lifetime recre-
ational use of psychedelics and elevated Openness
scores (D. Erritzoe, J. Smith, P. M. Fisher, R. Car-
hart-Harris, V. G. Frokjaer, G. M. Knudsen,
under review), it is possible that serotonin 2A
receptor function is linked to Openness. Evidence
from rodents suggests that cognitive ﬂexibility is in
part mediated via the 2A receptor (74), and, as dis-
cussed previously, a variety of 2A receptor ago-
nists, such as psilocybin, DMT, and LSD, are
associated with increased Openness, as well as
increased cognitive ﬂexibility and creative thinking
(75–79). Indeed, serotonin and more speciﬁcally,
serotonin 2A receptor stimulation has been associ-
ated with a relaxing of prior assumptions (80) –
which would ﬁt with the qualities of open-minded-
ness that characterize the Openness dimension.
More investigations into the role of serotonin 2A
receptors in mediating changes in Openness are
therefore clearly warranted.
In summary, our study detected changes in per-
sonality measures from baseline to 3 months post
psilocybin therapy in patients suﬀering major
depression. Decreases in Neuroticism and (trend-
level) increases in Conscientiousness were consis-
tent with what has been found previously among
patients responding to antidepressant treatment,
whereas pronounced increases in Extraversion and,
in particular, in Openness, might constitute an
eﬀect more speciﬁc to therapy with a psychedelic
than with other antidepressant interventions. This
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hypothesis needs to be explored further in future
controlled studies, however, as do the brain mech-
anisms of postpsychedelic personality change.
Finally, some preliminary evidence was found that
certain changes in personality were predicted by
the nature of the acute experience under psilocy-
bin, with acute Insight being particularly impli-
cated.
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